Results 161 to 170 of about 1,338,680 (315)

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma

Molecular Oncology, EarlyView.
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski, Júlia Perera‐Bel, Alejo Rodriguez‐Vida, Nuria Juanpere, Jihyun Lee, Daniel E. Michaud, Jennifer L. Guerriero, Kent W. Mouw, Aristotelis Bamias, Filipe L. F. Carvalho, Joaquim Bellmunt   +10 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Real-World Data as Real Evidence Showing Real-World Outcomes

Journal of Kidney Cancer
N ...
openaire   +2 more sources

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

Respiratory Research
Afisi S. Ismaila, Kieran J. Rothnie, Robert P. Wood, Victoria L. Banks, Lucinda J. Camidge, Alexandrosz Czira, Chris Compton, Raj Sharma, Shannon N. Millard, Olivia Massey, David M. G. Halpin   +10 more
doaj   +1 more source

Biliary Tract Carcinoma: Real-World Evidence in a Developing Country. [PDF]

Cureus
Lema M, Lema C, Preciado B, Hoyos Duque S, Luján M, Aguirre D, Bonilla C, Gómez D, Pérez E, Pineda M, Patiño S.   +10 more
europepmc   +1 more source

“Real-World Evidence?”

JACC: Cardiovascular Interventions, 2016
openaire   +3 more sources

What Can the World Bank Do to Foster Longer and More Productive Working Lives? - Rethink Social Protection and Jobs in an Actively Aging World

Recognizing that this agenda spans virtually all of the World Bank’s policy areas, this brief focuses on policies under the purview of the World Bank’s Social Protection and Jobs (SPJ) agenda, especially ...
World Bank
core   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Temozolomide reconsidered: Real-World evidence in resistant melanoma cases. [PDF]

Oncologist
Maselli-Schoueri JH, Martinez E, Lagos E, Campos EF, Saldanha EF, Muniz TP, Butler MO, Saibil SD.   +7 more
europepmc   +1 more source